ArticleJournal of neurovirology2026
Plasma suPAR and domain-specific cognitive performance in virologically suppressed women with HIV.
Article in Journal of neurovirology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cognitive impairment remains common among people living with HIV despite effective antiretroviral therapy, with women disproportionately affected. Identifying stable and scalable inflammatory biomarkers that reflect domain-specific vulnerability is important for improving risk assessment in this population. Soluble urokinase plasminogen activator receptor (suPAR) is a circulating marker of immune activation with established analytical stability and prognostic value across multiple inflammatory conditions, including HIV. However, its relationship to cognitive performance in virologically suppressed women living with HIV (WLWH) is not well characterized. We conducted a cross-sectional study of 200 virologically suppressed WLWH enrolled at the Chicago-Cook County site of the MWCCS. Plasma suPAR was measured using the suPARnostic® AUTO Flex ELISA. Cognitive performance was assessed using demographically adjusted T-scores across executive function, psychomotor speed, motor function, memory, attention/working memory, verbal fluency, and learning. Multivariable linear regression models examined associations between log-transformed suPAR and continuous cognitive scores, adjusting for menopause status and suPAR storage duration. Relationships between log-suPAR and odds of impairment (T-score ≤ 40) were examined in adjusted logistic regression models. A same-visit subset was analyzed to account for timing differences between blood collection and cognitive testing. Higher log-suPAR was associated with lower psychomotor speed, lower motor function, and lower global average cognition. Odds of impairment in psychomotor speed, and motor function were higher with increasing log-suPAR. Sensitivity analyses showed consistent effect directions and magnitudes. These findings suggest that elevated suPAR reflects inflammation-related, domain-specific cognitive vulnerability in virologically suppressed WLWH and warrants further evaluation in longitudinal studies; clinical translation will require validation in larger, more demographically diverse cohorts, with concurrent assessment of menopausal and vascular risk profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.